- Home
- NPCE vs PALI Comparison
NPCE vs PALI Comparison
Compare NPCE & PALI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$15.92
HOLD
Current Price
$1.84
Company Overview
Basic Information| Metric | NPCE | PALI |
|---|---|---|
| Founded | 1997 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 328.8M | 268.6M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | NPCE | PALI |
|---|---|---|
| Price | $15.92 | $1.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 1 |
| Target Price | ★ $17.29 | $16.00 |
| AVG Volume (30 Days) | 248.7K | ★ 5.0M |
| Earning Date | 11-04-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $94,864,000.00 | N/A |
| Revenue This Year | $24.82 | N/A |
| Revenue Next Year | $1.28 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 24.08 | N/A |
| 52 Week Low | $7.56 | $0.53 |
| 52 Week High | $18.98 | $3.30 |
Technical Indicators
Market Signals| Indicator | NPCE | PALI |
|---|---|---|
| Relative Strength Index (RSI) | 58.64 | 47.12 |
| Support Level | $16.00 | $1.73 |
| Resistance Level | $16.94 | $2.27 |
| Average True Range (ATR) | 0.69 | 0.19 |
| MACD | -0.17 | -0.02 |
| Stochastic Oscillator | 18.63 | 28.03 |
Price Performance
Historical Comparison NPCE
PALI
About NPCE Neuropace Inc.
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.
About PALI Palisade Bio Inc.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.